Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

[1]  [Amyloid imaging]. , 2016, Nihon rinsho. Japanese journal of clinical medicine.

[2]  Andrew J. Saykin,et al.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[3]  Harald Hampel,et al.  Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease , 2014, Neuropsychopharmacology.

[4]  Martina Bocchetta,et al.  Imaging markers for Alzheimer disease , 2013, Neurology.

[5]  B. Dubois,et al.  Measuring cognitive change in subjects with prodromal Alzheimer's disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  J. Huttunen,et al.  Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients , 2013, European journal of neurology.

[7]  Colin L. Masters,et al.  Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia , 2013, The Journal of Nuclear Medicine.

[8]  Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later , 2013, Neurology.

[9]  C. Jack,et al.  Application of the National Institute on Aging–Alzheimer’s Association AD criteria to ADNI , 2013, Neurology.

[10]  F. Pasquier,et al.  Emotional and psychological implications of early AD diagnosis. , 2013, The Medical clinics of North America.

[11]  Jagan A. Pillai,et al.  Clinical trials in predementia stages of Alzheimer disease. , 2013, The Medical clinics of North America.

[12]  M. Carrillo,et al.  CSF biomarker variability in the Alzheimer's Association quality control program , 2013, Alzheimer's & Dementia.

[13]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[14]  Yaakov Stern,et al.  Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease , 2013, Neurology.

[15]  Stephen F. Carter,et al.  Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease , 2013, Neurology.

[16]  Paul Maruff,et al.  Research and standardization in Alzheimer's trials: Reaching international consensus , 2013, Alzheimer's & Dementia.

[17]  Cindee M. Madison,et al.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. , 2013, Brain : a journal of neurology.

[18]  E. Teng,et al.  Clinicopathologic differences among patients with behavioral variant frontotemporal dementia , 2013, Neurology.

[19]  Sylvie Slaets,et al.  Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies. , 2013, Journal of Alzheimer's disease : JAD.

[20]  Olivier Colliot,et al.  Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia? , 2013, Alzheimer's & Dementia.

[21]  Eric M Reiman,et al.  Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study , 2012, The Lancet Neurology.

[22]  Kewei Chen,et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.

[23]  F. Amenta,et al.  Late and early onset dementia: What is the role of vascular factors? A retrospective study , 2012, Journal of the Neurological Sciences.

[24]  G. Chételat,et al.  Region-Specific Hierarchy between Atrophy, Hypometabolism, and β-Amyloid (Aβ) Load in Alzheimer's Disease Dementia , 2012, The Journal of Neuroscience.

[25]  Y. Stern.  Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[26]  S. Arnold,et al.  [18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies , 2012, Acta Neuropathologica.

[27]  Matthew L Senjem,et al.  Indicators of amyloid burden in a population-based study of cognitively normal elderly , 2012, Neurology.

[28]  Reisa A. Sperling,et al.  Subjective cognitive complaints and amyloid burden in cognitively normal older individuals , 2012, Neuropsychologia.

[29]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[30]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[31]  Anders M. Dale,et al.  Rates of Decline in Alzheimer Disease Decrease with Age , 2012, PloS one.

[32]  Susanne Graef,et al.  Using the Rey Auditory Verbal Learning Test (RAVLT) to Differentiate Alzheimer's Dementia and Behavioural Variant Fronto-Temporal Dementia , 2012, The Clinical neuropsychologist.

[33]  Jason D. Warren,et al.  The paradox of syndromic diversity in Alzheimer disease , 2012, Nature Reviews Neurology.

[34]  A. Wall,et al.  Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers , 2012, Neurology.

[35]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[36]  H. Soininen,et al.  CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings , 2012, Neurology.

[37]  Kewei Chen,et al.  Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with 18F-FDG PET: Head-to-Head Comparison , 2012, The Journal of Nuclear Medicine.

[38]  Nick C Fox,et al.  Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[39]  Mario A. Parra,et al.  Short-term memory binding is impaired in AD but not in non-AD dementias , 2012, Neuropsychologia.

[40]  C. Jack,et al.  Modifiable factors that alter the size of the hippocampus with ageing , 2012, Nature Reviews Neurology.

[41]  Charles D. Smith,et al.  Preclinical AD Workgroup staging: pathological correlates and potential challenges , 2012, Neurobiology of Aging.

[42]  M. Mintun,et al.  Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.

[43]  J Schröder,et al.  Age and diagnostic performance of Alzheimer disease CSF biomarkers , 2012, Neurology.

[44]  J. Cummings,et al.  Cerebrospinal Fluid Biomarkers and Proximity to Diagnosis in Preclinical Familial Alzheimer’s Disease , 2012, Dementia and Geriatric Cognitive Disorders.

[45]  F. Jessen,et al.  Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease , 2012, Neurology.

[46]  J. Molinuevo,et al.  Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD , 2012, International journal of geriatric psychiatry.

[47]  B. Dickerson,et al.  MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults , 2012, Neurology.

[48]  W. M. van der Flier,et al.  Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort , 2012, Neurology.

[49]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[50]  N. Bohnen,et al.  Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.

[51]  H. Vanderstichele,et al.  Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. , 2012, Journal of Alzheimer's disease : JAD.

[52]  David Bartrés-Faz,et al.  Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[53]  Clifford R Jack,et al.  Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.

[54]  C. Marra,et al.  Probable Alzheimer's Disease Patients Presenting as “Focal Temporal Lobe Dysfunction” Show a Slow Rate of Cognitive Decline , 2011, Journal of the International Neuropsychological Society.

[55]  J. Trojanowski,et al.  Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. , 2011, Archives of neurology.

[56]  Luca Pani,et al.  Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden — Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials , 2011, European Neuropsychopharmacology.

[57]  J. Karlawish.  Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease , 2011, Neurology.

[58]  Mariko Yoshino,et al.  [The logopenic variant of primary progressive aphasia]. , 2011, Brain and nerve = Shinkei kenkyu no shinpo.

[59]  Kirrie J Ballard,et al.  Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging. , 2011, Brain : a journal of neurology.

[60]  Alan E Hubbard,et al.  Longitudinal change of biomarkers in cognitive decline. , 2011, Archives of neurology.

[61]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[62]  Julie S Snowden,et al.  The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. , 2011, Brain : a journal of neurology.

[63]  A. Fagan,et al.  Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. , 2011, Archives of neurology.

[64]  A. Dale,et al.  Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease , 2011, Neurology.

[65]  P. Caramelli,et al.  The Pietà study: epidemiological investigation on successful brain aging in Caeté (MG), Brazil. Methods and baseline cohort characteristics. , 2011, Arquivos de neuro-psiquiatria.

[66]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[67]  J. Molinuevo,et al.  Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid ß-Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas , 2011, Biological Psychiatry.

[68]  Olivier Colliot,et al.  Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease. , 2011, Brain : a journal of neurology.

[69]  Karl Herholz,et al.  Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.

[70]  Giovanni B. Frisoni,et al.  The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.

[71]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[72]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[73]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[74]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[75]  G. Rabinovici,et al.  Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution , 2011, Neurology.

[76]  Andrea Ciarmiello,et al.  PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research , 2011, Journal of cellular physiology.

[77]  J O Rinne,et al.  Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.

[78]  Robert A. Dean,et al.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.

[79]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[80]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[81]  M. Viitanen,et al.  Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers. , 2011, Journal of Alzheimer's disease : JAD.

[82]  D. Aarsland,et al.  Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. , 2011, Neuropsychology.

[83]  P. Deyn,et al.  Added diagnostic value of CSF biomarkers in differential dementia diagnosis , 2010, Neurobiology of Aging.

[84]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[85]  C. D. de Jager,et al.  Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post‐mortem diagnosis , 2010, International journal of geriatric psychiatry.

[86]  Francisco Lopera,et al.  Visual short-term memory binding deficits in familial Alzheimer's disease. , 2010, Brain : a journal of neurology.

[87]  M. Sarazin,et al.  Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[88]  H. Brodaty,et al.  Does executive impairment define a frontal variant of Alzheimer's disease? , 2010, International Psychogeriatrics.

[89]  G. Ridgway.  CLINICAL SYNDROMES ASSOCIATED WITH POSTERIOR ATROPHY: EARLY AGE AT ONSET AD SPECTRUM , 2010, Neurology.

[90]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[91]  G. Frisoni,et al.  The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment , 2010, Alzheimer's & Dementia.

[92]  F. Barkhof,et al.  New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic Population , 2010, Dementia and Geriatric Cognitive Disorders.

[93]  F. Huppert,et al.  Theoretical exploration of the neural bases of behavioural disinhibition, apathy and executive dysfunction in preclinical Alzheimer's disease in people with Down's syndrome: potential involvement of multiple frontal-subcortical neuronal circuits. , 2010, Journal of intellectual disability research : JIDR.

[94]  Wiro J Niessen,et al.  A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. , 2010, Brain : a journal of neurology.

[95]  K. Jellinger,et al.  Prevalence of dementia disorders in the oldest-old: an autopsy study , 2010, Acta Neuropathologica.

[96]  Li Yao,et al.  Impairment and compensation coexist in amnestic MCI default mode network , 2010, NeuroImage.

[97]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[98]  L. Sambati,et al.  Are subjective cognitive complaints a risk factor for dementia? , 2010, Neurological Sciences.

[99]  J. Hodges,et al.  How preserved is episodic memory in behavioral variant frontotemporal dementia? , 2010, Neurology.

[100]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[101]  H. Feldman,et al.  Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study , 2010, Journal of the Neurological Sciences.

[102]  P. Scheltens,et al.  Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe , 2010, European journal of neurology.

[103]  D. Chudy,et al.  Frontal Variant of Alzheimer's Disease: Clinico-CSF-Pathological Correlation , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[104]  H. Engler,et al.  High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. , 2009, Current Alzheimer research.

[105]  N. Burgess,et al.  Topographical short‐term memory differentiates Alzheimer's disease from frontotemporal lobar degeneration , 2009, Hippocampus.

[106]  Andrew Kertesz,et al.  Differentiating the frontal variant of Alzheimer's disease , 2009, International journal of geriatric psychiatry.

[107]  P. Visser,et al.  Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. , 2010, Journal of Alzheimer's disease : JAD.

[108]  Olivier Colliot,et al.  The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study. , 2010, Journal of Alzheimer's disease : JAD.

[109]  Carol Brayne,et al.  Age, neuropathology, and dementia. , 2009, The New England journal of medicine.

[110]  Mark A Mintun,et al.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. , 2009, Archives of neurology.

[111]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[112]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[113]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[114]  R De Raedt,et al.  Verbal cued recall as a predictor of conversion to Alzheimer's disease in Mild Cognitive Impairment , 2009, International journal of geriatric psychiatry.

[115]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[116]  K. Limem,et al.  Evaluation of Cerebrospinal Fluid Tau/Beta-Amyloid(42) Ratio as Diagnostic Markers for Alzheimer Disease , 2009, European Neurology.

[117]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[118]  D. Knopman,et al.  Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI , 2009, Neurology.

[119]  P. Deyn,et al.  Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P , 2009, Neurochemistry International.

[120]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[121]  Nelleke Tolboom,et al.  Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding , 2009, Journal of Nuclear Medicine.

[122]  Li Shen,et al.  Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.

[123]  W. Jagust.  Amyloid + Activation = Alzheimer's? , 2009, Neuron.

[124]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[125]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[126]  A. Drzezga,et al.  Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.

[127]  A. Fagan,et al.  Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. , 2009, Archives of neurology.

[128]  W. M. van der Flier,et al.  A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease , 2009, Annals of clinical biochemistry.

[129]  K. Blennow,et al.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment , 2009, Neurobiology of Aging.

[130]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[131]  K. Narasimhalu,et al.  Differences Exist in the Cognitive Profile of Mild Alzheimer’s Disease and Subcortical Ischemic Vascular Dementia , 2009, Dementia and Geriatric Cognitive Disorders.

[132]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[133]  Keith A. Johnson,et al.  Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.

[134]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[135]  H. Benali,et al.  Support vector machine-based classification of Alzheimer’s disease from whole-brain anatomical MRI , 2009, Neuroradiology.

[136]  Johannes Kornhuber,et al.  Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease , 2009, Journal of Neural Transmission.

[137]  Rachel L. Mistur,et al.  FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[138]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[139]  D. Perani,et al.  Education and occupation as proxies for reserve in aMCI converters and AD , 2008, Neurology.

[140]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[141]  W. Jagust,et al.  Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.

[142]  N. Fayed,et al.  Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. , 2008, Academic radiology.

[143]  D. Geschwind,et al.  Biochemical markers in persons with preclinical familial Alzheimer disease , 2008, Neurology.

[144]  Georgina Johanna Lowndes,et al.  Recall and recognition of verbal paired associates in early Alzheimer's disease , 2008, Journal of the International Neuropsychological Society.

[145]  Lippincott Williams Wilkins,et al.  THERMOREGULATION: RECENT CONCEPTS AND REMAINING QUESTIONS , 2008, Neurology.

[146]  J. Trojanowski,et al.  CSF biomarkers in frontotemporal lobar degeneration with known pathology , 2008, Neurology.

[147]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[148]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[149]  B. L. Beattie,et al.  Cognitive Impairment No Dementia – Neuropsychological and Neuroimaging Characterization of an Amnestic Subgroup , 2008, Dementia and Geriatric Cognitive Disorders.

[150]  J. Hodges,et al.  Predicting Rapid Clinical Progression in Amnestic Mild Cognitive Impairment , 2008, Dementia and Geriatric Cognitive Disorders.

[151]  Julie S. Snowden,et al.  Cognitive Phenotypes in Alzheimer's Disease and Genetic Risk , 2007, Cortex.

[152]  P. Scheltens,et al.  The significance of medial temporal lobe atrophy , 2007, Neurology.

[153]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[154]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[155]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[156]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[157]  I. McKeith,et al.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.

[158]  H. Chiu,et al.  Relevance of outcome measures in different cultural groups – does one size fit all? , 2007, International Psychogeriatrics.

[159]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[160]  Kiralee M. Hayashi,et al.  The topography of grey matter involvement in early and late onset Alzheimer's disease. , 2007, Brain : a journal of neurology.

[161]  G. Schellenberg,et al.  CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. , 2007, Neurology.

[162]  H. Soininen,et al.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[163]  G. Hajak,et al.  Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample , 2006, Neurobiology of Aging.

[164]  E Guedj,et al.  Identification of subgroups in amnestic mild cognitive impairment , 2006, Neurology.

[165]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[166]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[167]  P. Modrego,et al.  Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. , 2006, Current Alzheimer research.

[168]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[169]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[170]  D. Perani,et al.  Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. , 2005, Archives of neurology.

[171]  J. Morris,et al.  Verbal and visuospatial deficits in dementia with Lewy bodies , 2005, Neurology.

[172]  E B Larson,et al.  Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both , 2005, Neurology.

[173]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[174]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[175]  R. Birrer,et al.  Depression in later life: a diagnostic and therapeutic challenge. , 2004, American family physician.

[176]  E. Barbeau,et al.  Evaluation of visual recognition memory in MCI patients , 2004, Neurology.

[177]  J. Schneider,et al.  Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology , 2004, Neurology.

[178]  M. Albert,et al.  For Personal Use. Only Reproduce with Permission the Lancet Publishing Group. Personal View Mci or Prodromal Ad? Clinical Relevance of the Concept of Mci Clinical Limitations of Mci Amnestic Mci or Prodromal Alzheimer's Disease? , 2022 .

[179]  P. Fossati,et al.  Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression. , 2004, Journal of psychiatric research.

[180]  P. R. Hof,et al.  Quantitative neuropathologic analysis of Pick's disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer's disease , 1994, Acta Neuropathologica.

[181]  H. Möller,et al.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. , 2004, Molecular psychiatry.

[182]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[183]  Jean-Claude Baron,et al.  Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons , 2003, NeuroImage.

[184]  J. Kulisevsky,et al.  Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging , 2003, International journal of geriatric psychiatry.

[185]  G. Small,et al.  Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. , 2003, Molecular Genetics and Metabolism.

[186]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[187]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[188]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[189]  Clifford R Jack,et al.  Neuroimaging in Alzheimer disease: an evidence-based review. , 2003, Neuroimaging clinics of North America.

[190]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[191]  B. Dubois,et al.  ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. , 2002, Presse medicale.

[192]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[193]  J. Semple,et al.  Paired associate performance in the early detection of DAT , 2002, Journal of the International Neuropsychological Society.

[194]  M. Bobinski,et al.  Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[195]  G. Binetti,et al.  A brief neuropsychological assessment for the differential diagnosis between frontotemporal dementia and Alzheimer's disease , 2001, European journal of neurology.

[196]  C. Marra,et al.  Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment , 2001, Journal of neurology, neurosurgery, and psychiatry.

[197]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[198]  K Patterson,et al.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. , 2000, Brain : a journal of neurology.

[199]  I Litvan,et al.  Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias , 1999, Neurology.

[200]  C. Cotman,et al.  Clinical and pathological evidence for a frontal variant of Alzheimer disease. , 1999, Archives of neurology.

[201]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[202]  D. Neary,et al.  Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer’s disease and frontotemporal dementia , 1999, Journal of neurology, neurosurgery, and psychiatry.

[203]  B. Dubois,et al.  Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease. , 1999, Alzheimer disease and associated disorders.

[204]  F. Pasquier,et al.  Explicit Memory in Frontotemporal Dementia: The Role of Medial Temporal Atrophy , 1998, Dementia and Geriatric Cognitive Disorders.

[205]  K Patterson,et al.  Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[206]  J. Becker,et al.  Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline , 1996, Neurology.

[207]  J. Rapoport,et al.  Reliability of cerebral measures in repeated examinations with magnetic resonance imaging , 1995, Psychiatry Research: Neuroimaging.

[208]  Richard S. J. Frackowiak,et al.  Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease , 1995, Neuroscience Letters.

[209]  Y. Agid,et al.  Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases , 1994, Neurology.

[210]  E. Tangalos,et al.  Memory function in normal aging , 1992, Neurology.

[211]  J. Harrison,et al.  Posterior cortical atrophy. , 1989, Clinical and experimental neurology.

[212]  H. Buschke,et al.  Screening for dementia by memory testing , 1988, Neurology.